Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02233322 · ClinicalTrials.gov registry record · NA
Iron Therapy for Autosomal Dominant Hypophosphatemic Rickets: A Pilot Project.
A NA study, sponsored by Indiana University.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT02233322: Completed NA study, sponsored by Indiana University.
NCT02233322 is a NA study that has completed, run by Indiana University. The registered enrollment target is 8 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02233322, a NA study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of the study is to gain a better understanding of the effect of iron on fibroblast growth factor 23 (FGF23) in the inherited disorder, autosomal dominant hypophosphatemic rickets (ADHR). ADHR is an inherited disorder in which the body makes too much FGF 23 and causes low blood phosphorus levels and bone problems such as rickets (bowed legs in children) or bone pain and weakness in adults. This study is to test whether or not giving iron helps correct the high FGF23 and there by correcting the phosphate problem.
Primary Outcome
Perform a pilot study in ADHR patients with low serum iron concentrations (defined below) to determine if increasing serum iron concentrations above 100 mcg/dl results in a decrease in intact FGF23 (primary endpoint) and C-terminal FGF23 concentrations by at least 20% and normalizes serum phosphorus and TMP/GFR (tubular maximum phosphate reabsorption/ glomerular filtration rate) within 6 months of attaining goal iron concentrations.
Interventions
- DIETARY_SUPPLEMENT Iron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-08 |
| Est. Completion | 2019-11-12 |
| Phase | NA |
What the finished NCT02233322 record still lists
NCT02233322 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Iron is the first listed.
NCT02233322 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02233322 about?
NCT02233322 is a clinical study titled "Iron Therapy for Autosomal Dominant Hypophosphatemic Rickets: A Pilot Project.". The purpose of the study is to gain a better understanding of the effect of iron on fibroblast growth factor 23 (FGF23) in the inherited disorder, autosomal dominant hypophosphatemic rickets (ADHR). ADHR is an inherited disorder in which the body makes too much FGF 23 and causes low blood phosphorus...
What is the current status of trial NCT02233322?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2014-08. Estimated completion is 2019-11-12.
What interventions are being tested in trial NCT02233322?
The interventions under investigation include: Iron (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02233322?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02233322's enrollment target sits among peer trials
8 1976th of 2000 higher than 19 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia